Efficacy in Hemophilia With Inhibitors

How NovoSeven® RT Works With Inhibitors

For people with hemophilia with inhibitors, the usual treatment—replacing the missing Factor VIII or Factor IX—may not work. This is because their bodies treat the factor as an invader, attacking and neutralizing the factor.

NovoSeven® RT "outsmarts" inhibitors by completely bypassing them in the coagulation process. Increasing the levels of activated Factor VII leads to activation of Factor X directly on the surface of activated platelets. This leads to the production of thrombin, and, in turn, begins the formation of a stable clot.

Efficacy in Bleeding Episodes

People with inhibitors most frequently bleed in the joints. Clinical data have demonstrated that recombinant Factor VIIa has a response rate of 91% in joint bleeds and 86% in muscle bleeds in as few as 5 hours.

efficacy hemophilia with inhibitors

This graph represents data from a double-blind, randomized, multicenter study of patients with hemophilia A or B with and without inhibitors. For patients who received a 70-mcg/kg dose and could be treated with a maximum of three doses, the mean number of doses used for joint bleeds and muscle bleeds was 2.2 and 2.1, respectively. These percentages reflect the number of patients reporting an excellent, effective, or partially effective result.

Efficacy in Surgery in Hemophilia With Inhibitors

Recombinant Factor VIIa has been shown to effectively control bleeding during surgical procedures in people with inhibitors. Four separate studies involving more than 200 procedures showed that Recombinant Factor VIIa was effective and safe.

The following information describes the effectiveness of recombinant Factor VIIa based on clinical trials:

  • Recombinant Factor VIIa is 85% effective at controlling surgical bleeding in patients at the recommended dose in randomized studies
  • Recombinant Factor VIIa was considered effective in 153 of 188 procedures
  • Recombinant Factor VIIa is effective in both major and minor surgery